New drug cocktail takes on rare skin cancer
Disease control
Not yet recruiting
This Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if …
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC